Proteome Systems Ltd and Iberica Co announced an agreement to collaborate on a proteomics and glycomics research program to analyse the proteoglycan changes associated with the progression and treatment of osteoarthritis. Proteoglycans are a major component of the cartilage in joints and contribute towards the lubrication of the articulating surface in the knee.

Dr. Nicolle Packer, Executive VP Glycoproteomics, Proteome Systems, said, "The chronic inflammatory process seen in osteoarthritis results in the loss of cartilage matrix in over 80% of middle-aged individuals, causing severe musculoskeletal pain and disability. The socio-economic consequences of osteoarthritis are considerable and are escalating as people live longer. We have the technology to be able to measure the effects of this process and to find markers which will enable us to detect and monitor disease progression/regression and response to treatment, earlier than is possible in the clinic today."

"This program is part of an Iberica-Kurume Translational Research Center collaboration with Professor Kensei Nagata, Chief Director of Department of Orthopaedics, Kurume University, to find a biomarker which may be used for diagnosis and/or treatment of osteoarthritis," said Misayo Abe, CEO, Iberica. "There is currently no available, accurate biochemical measure of the course, or treatment, of this widespread disease. Proteome Systems will conduct the proteomic research in their Sydney laboratories on patient samples provided by Iberica-Kurume."